TNF Pharmaceuticals, Inc. financial data

Symbol
TNFA on Nasdaq
Location
1185 Avenue Of The Americas, Suite 249, New York, NY
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 19, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 137 % -14.1%
Debt-to-equity 86.9 % -19.5%
Return On Equity -81.9 % +66.1%
Return On Assets -33 % +71.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 4.17M shares
Common Stock, Shares, Outstanding 2.98M shares +20.5%
Entity Public Float 3.79M USD -94%
Common Stock, Value, Issued 112M USD +3.92%
Weighted Average Number of Shares Outstanding, Basic 1.48M shares +5856%
Weighted Average Number of Shares Outstanding, Diluted 1.48M shares +5856%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 3.91M USD -25.8%
General and Administrative Expense 3.67M USD -17.1%
Operating Income (Loss) -8.32M USD +35.4%
Nonoperating Income (Expense) 525K USD -886%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -7.8M USD +67%
Net Income (Loss) Attributable to Parent -7.8M USD +67%
Earnings Per Share, Basic 103 USD/shares +97.7%
Earnings Per Share, Diluted 103 USD/shares +97.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 73.2K USD -67.5%
Marketable Securities, Current 3.09M USD -67.3%
Assets, Current 11.1M USD -7.32%
Operating Lease, Right-of-Use Asset 2.68K USD -92.3%
Goodwill 10.5M USD 0%
Assets 37.2M USD +54.9%
Accounts Payable, Current 3.18M USD -23.5%
Accrued Liabilities, Current 429K USD -16.1%
Liabilities, Current 6.53M USD -6.51%
Operating Lease, Liability, Noncurrent 20.5K USD -78%
Liabilities 15.9M USD +128%
Retained Earnings (Accumulated Deficit) -138M USD -9.17%
Stockholders' Equity Attributable to Parent 14.3M USD -14.6%
Liabilities and Equity 37.2M USD +54.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -2.64M USD -50.3%
Net Cash Provided by (Used in) Financing Activities -1.43M USD -110%
Net Cash Provided by (Used in) Investing Activities 2.54M USD +247%
Common Stock, Shares Authorized 1.25B shares +400%
Common Stock, Shares, Issued 2.98M shares +20.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -99.9K USD +95.9%
Deferred Tax Assets, Valuation Allowance 36.1M USD +19.9%
Operating Lease, Liability 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid 2.7K USD -92.6%
Operating Lease, Liability, Current 2.68K USD -92.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two 10.8K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 2.7K USD -92.6%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 221 USD -77.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 5.81K USD 0%
Deferred Tax Assets, Operating Loss Carryforwards 27.9M USD +5.19%
Preferred Stock, Shares Authorized 50M shares 0%
Operating Lease, Payments 8.1K USD -13.2%
Additional Paid in Capital 152M USD +6.26%
Share-based Payment Arrangement, Expense 12.2K USD -95.9%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%